Multaq (dronedarone): Drug Safety Communication – Increased Risk of Death or Serious Cardiovascular Events

Audience: Healthcare Professionals ISSUE: FDA notified healthcare professionals that it is reviewing data from a clinical trial that evaluated the effects of the antiarrhythmic drug Multaq (dronedarone) in patients with permanent atrial…

Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication – Potential Increased Risk of Esophageal Cancer Audience: Geriatrics, Family Practice, Internal Medicine Includes: Fosamax (alendronate), Actonel...

FREE Case Review

Defective DrugsAdverse reactions to medications on the market.

Personal InjuryPersonal injuries resulting from negligence may lead to significant medical expenses.

Toxic ExposureDangerous toxins linked to cancers, birth defects, and chronic respiratory problems.

DiseasesDangerous toxins linked to cancers, birth defects, and chronic respiratory problems.

Financial FraudsUnethical actions by large corporations may cause financial hardship.

Medical MalpracticeMedical errors or negligent health care resulting in injury or death.

Multaq (dronedarone): Drug Safety Communication – Increased Risk of Death or Serious Cardiovascular Events

FREE Case Review

Trending Topics